Utility of thymosin α-1 (Zadaxin™) as a co-adjuvant in influenza vaccines: A review

Journal of Preventive Medicine and Hygiene

Volumn 52, Issue 3, 2011, Pages 111-115

  Panatto, Donatella ^a   Amicizia, D ^a   Lai, P L ^a   Camerini, R ^b   De Rosa, A ^b   Gasparini, R ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b Sigma Tau SpA   (Italy)

Author keywords

Elderly; Immunocompromised subjects; Influenza vaccine; Thymosin alfa 1; Zadaxin

Indexed keywords

ALPHA INTERFERON; ALUMINUM POTASSIUM SULFATE; CHEMOKINE; DIPHTHERIA TOXOID; GAMMA INTERFERON; HEPATITIS B VACCINE; I KAPPA B KINASE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INDOLEAMINE 2,3 DIOXYGENASE; INFLUENZA VACCINE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; LIPOSOME; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MIFAMURTIDE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MYELOID DIFFERENTIATION FACTOR 88; THYMOSIN ALPHA1; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; VIROSOME;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; APOPTOSIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CROSS REACTION; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG EFFICACY; DRUG MECHANISM; HELPER CELL; HEMODIALYSIS PATIENT; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOGENICITY; IMMUNOREGULATION; IMMUNOSTIMULATION; INFECTION RISK; INFLUENZA; INFLUENZA VACCINATION; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMACYTOID DENDRITIC CELL; REVIEW; SYSTEMATIC REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH17 CELL; VIRUS REPLICATION;

ADJUVANTS, IMMUNOLOGIC; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; THYMOSIN;

EID: 80052925467     PISSN: 11212233     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Fiebach N, Beckett W. Prevention of respiratory infections in adults: influenza and pneumoccocal vaccines. Arch Intern Med 1994;154:2545-57. (Pubitemid 24362405)
2. Center for Disease Control and Prevention. Seasonal Influenza. http://www.cdc.gov/flu/about/qa/disease.htm [Accessed on October 9, 2010].
3. Sullivan KM. Health impact of influenza in United States. Pharmacoeconomics 1996;9:26-33. (Pubitemid 26308765)
4. Fleming DM, Elliot AJ. Lessons from 40 years' surveillance of influenza in England and Wales. Epidemiol Infect 2008;136:866-75. (Pubitemid 351712521)
5. Sarnak MJ, Jaber BL. Mortality caused by sepsis in patients with end-stage renal disease compared with the general population. Kidney Int 2000;58:1758-64.
6. Johnson DW, Fleming SJ. The use of vaccines in renal failure. Clin Pharmacokinet 1992;22:434-46.
7. Cappel R, Van Beers D, Liesnard C, et al. Impaired humoral and cell-mediated immune response in dialyzed patients after influenza vaccination. Nephron 1983;33:21-5. (Pubitemid 13173057)
8. Nordin J, Mullooly J, Poblete S, et al. Influenza vaccine effectiveness in preventing hospitalizations and deaths in persons 65 years or older in Minnesota, New York, and Oregon: data from 3 health plans. J Infect Dis 2001;184:665-70. (Pubitemid 32826416)
9. Fiore AE, Shay DK, Broder K, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep 2008;57:1-60.
10. WHO: Global Influenza Programme. http://www.who.int/csr/disease/ influenza/mission/en/index.html
11. Nichol KL, Nordini JD, Nelson DB, et al. Efectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med 2007;357:1373-81. (Pubitemid 47535592)
12. Thijs C, Beyer WE, Govaert PM, et al. Mortality benefits of influenza vaccination in elderly people. Lancet Infect Dis 2008;8:460-1. (Pubitemid 352001406)
13. Chiatti C, Barbadoro P, Lamura G, et al. Influenza vaccine uptake among community-dwelling Italian ederly: results from a large cross-sectional study. BMC Public Health 2011;11:207.
14. Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 2001;19:2673-80. (Pubitemid 32234288)
15. Panatto D, Lai P, Gasparini R. Today's Influenza Vaccines - Why an adjuvant is needed and how it works. Eur Infect Dis 2010;4:36-40.
16. Goldstein AL, Slater FD, White A. Preparation, assay and partial purification of a thymic lymphocytopoietic factor [Thymosin]. Proc Natl Acad Sci U S A 1966;56:1010-7.
17. Goldstein AL, Low TL, McAdoo M, et al. Thymosin alpha 1: isolation and sequence analysis of an immunologically active thymic polypepetide. Proc Natl Acad Sci U S A 1977;74:725-9. (Pubitemid 8038798)
18. Goldstein AL, Badamchian M. Thymosins: chemistry and biological properties in health and diseases. Expert Opin Biol Ther 2004;4:559-73. (Pubitemid 38480555)
19. Low T, Goldstein A. Role of the Thymosine as immunomodulating agents and maturation factors. In: Moore MA, ed. Maturation Factors and Cancer. New York: Raven 1982, pp. 129-52.
20. Low T, Goldstein A. Thymosin, peptidemoieties, and related agents. In: Fenichel RL, Chirigus MA, eds. Immune Modulation Agents and Their Mechanisms. New York: Dekker 1984, pp. 135-62.
21. Ahmed A, Wong DM, Thurman GB, et al. T-lymphocyte maturation: cell surface markers and immune function induced by lymphocyte cell-free products and thymosin polypeptides. Ann N Y Acad Sci 1979;332:81-94.
22. Peng Y, Chen Z, Yu W, et al. Effects of thymic polypeptides on the thymopoiesis of mouse embryonic stem cells. Cell Biol Int 2008;32:1265-71.
23. Yao Q, Doan LX, Zhang R, et al. Thymosin-alpha1 modulates dendritic cell differentiation and functional maturation from human peripheral blood CD14+ monocytes. Immunol Lett 2007;110:110-20. (Pubitemid 46839137)
24. Rustgi VK. Thymalfasin for the treatment of chronic hepatitis C infection. Expert Rev Anti Infect Ther 2005;3:885-92. (Pubitemid 41782589)
25. Leichtling KD, Serrate SA, Sztein MB. Thymosin alpha 1 modulates the expression of high affinity interleukin-2 receptors on normal human lymphocytes. Int J Immunopharmacol 1990;12:19-29. (Pubitemid 20034207)
26. Andreone P, Gramenzi A, Cursaro C, et al. Thymosin-alpha 1 plus interferon-alpha for naive patients with chronic hepatitis. J Viral Hepat 2004;11:69-73.
27. Garaci E, Favalli C, Pica F, et al. Thymosin alpha 1: from bench to bedside. Ann N Y Acad Sci 2007;1112:225-34. (Pubitemid 47598679)
28. Garaci E, Pica F, Sinibaldi-Vallebona P, et al. Thymosin alpha(1) in combination with cytokines and chemotherapy for the treatment of cancer. Int Immunopharmacol 2003;3:1145-50. (Pubitemid 36833274)
29. Naylor PH, Quadrini K, Garaci E, et al. Immunopharmacology of thymosin alpha1 and cytokine synergy. Ann N Y Acad Sci 2007;1112:235-44. (Pubitemid 47598674)
30. Sungarian A, Cielo D, Sampath P, et al. Potential Role of Thymosin-alpha1 Adjuvant Therapy for Glioblastoma. J Oncol 2009;2009:302084.
31. Zhang P, Chan J, Dragoi AM, et al. Activation of IKK by thymosin α1 requires the TRAF6 signalling pastway. EMBO Rep 2005;6:537.
32. Romani L, Bistoni F, Montagnoli C, et al. Thymosin α1 and endogenous regulator of inflammation, immunity, and tolerance. Ann N Y Acad Sci 2007;1112:326-38. (Pubitemid 47598643)
33. Romani L, Bistoni F, Perruccio K, et al. Thymosin alpha1 activated dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. Blood 2006;108:2265-74. (Pubitemid 44497509)
34. Qin Y, Chen FD, Zhou L, et al. Proliferative and anti-proliferatie effects of thymosin alpha1 on cells are associated with manipulation of cellular ROS levels. Chem Biol Interact 2009;180:383-8.
35. Bonifazi P, D'Angelo C, Fallarino F, et al. Thymosin α1: the regulator of regulators? Ann N Y Acad Sci 2010;1194:1-5.
36. Bernstein E, Kaye D, Abrutyn, et al. Immune response to influenza vaccination in a large-scale healthy elderly population. Vaccine 1999;17:82-94. (Pubitemid 28470736)
37. Taub DD, Longo DL. Insights into thymic aging and regeneration. Immunol Rev 2005;205:72-93. (Pubitemid 40780178)
38. Jefferson T, Rivetti D, Rivetti A, et al. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet 2005;366:1165-74. (Pubitemid 41393594)
39. Gasparini R, Lucioni C, Lai P, et al. Influenza surveillance in the Italian region of Liguria in the winter of 1999-2000 by general practitioners and paediatricians: socio-economic implications. J Prev Med Hyg 2001;42:83-6.
40. Gasparini R, Lucioni C, Lai P, et al. Valutazione benefici-costi della vaccinazione antinfluenzale negli anziani in Liguria. PharmacoEconomics Italian Research Articles 2003;5:23-30. (Pubitemid 36553336)
41. Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2005;24:1159-69.
42. Gravenstein S, Drinka P, Duthie EH, et al. Efficacy of an influenza hemagglutinin-diphtheria toxoid conjugate vaccine in elderly nursing home subjects during an influenza outbreak. J Am Geriatr Soc 1994;42:245-51. (Pubitemid 24079864)
43. Gross PA, Quinnan GV, Weksler ME et al. Immunization of elderly people with high doses of influenza vaccine. J Am Geriatr Soc 1988;36:209-12. (Pubitemid 18078054)
44. Gasparini R, Pozzi T, Montomoli E, et al. Increased immunogenicity of the MF59-adjuvated influenza vaccine compared to a conventional subunit vaccine in elderly subjects. Eur J Epidemiol 2001;17:135-40. (Pubitemid 32900039)
45. Banzhoff A, Gasparini R, Laghi-Pasini F, et al. MF59-adjuvated H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS One 2009;4:e4384.
46. Gasparini R, Schioppa F, Lattanzi M, et al. Impact of prior or concomitant seasonal influenza vaccination on MF59-adjuvated H1N1v vaccine (Focetria) in adult and elderly subjects. Int J Clin Pract 2010;64:432-8.
47. Ershler WB, Hebert JC, Blow AJ, et al. Effect of thymosin alpha one on specific antibody response and susceptibility to infection in young and aged mice. Int J Immunopharmacol 1985;7:465-71. (Pubitemid 15233466)
48. Effros RB, Casillas A, Walford RL. The effect of Thymosin-α1 on immunity to influenza in aged mice. Aging-Immunology and Infectious Disease 1988;1:31-40.
49. Ershler W, Moore A, Socinski M. Influenza and aging: age-related changes and the effects of thymosin on the antibody response to influenza vaccine. J Clin Immunol 1984;4:445-54. (Pubitemid 15217438)
50. Ershler WB, Gravenstein S, Geloo ZS. Thymosin alpha 1 as an adjunct to influenza vaccination in the elderly: rationale and trial summaries. Ann N Y Acad Sci 2007;1112:375-84. (Pubitemid 47598685)
51. Gravenstein S, Ershler WB, Drumaskin S, et al. Anti-influenza antibody response: augmentation in elderly "non-responders"by thymosin alpha 1. Gerontologist 1986;26:150a.
52. Gravenstein S, Duthie EH, Miller BA, et al. Augmentation of influenza antibody response in elderly men by thymosin alpha one. A double-blind placebo-controlled clinical study. J Am Geriatr Soc 1989;37:1-8. (Pubitemid 19032310)
53. McConnell L, Gravenstein S, Roecker E, et al. Augmentation of influenza antibody levels and reduction in attack rates in elderly subjects by thymosin alpha 1. Gerontologist 1989;29:188a.
54. Tuthill C, De Rosa A, Camerini R, et al. The Immunomodulatory peptide Thymosin Alpha 1 enhances response to influenza vaccine. The Trirteenth Annual Conference on Vaccine Research. Bethesda, MD USA April 26-28, 2010. Abstract book available at http://www.nfid.org/pdf/conference/vaccine10abstracts.pdf
55. Shen SY, Corteza QB, Josselson J, et al. Age-dependent enhancement of influenza vaccine responses by thymosin in chronic hemodialysis patients. In: Goldstein AL, ed. Biomedical Advances in Ageing. New York: Plenum Press 1990, pp. 523-30.
56. Steve Y, Shen S, Josselson J, et al. Effect of thymosin alpha 1 on heptavax-B vaccination among hemodialysis patients. Kidney Int 1987;31:217.
57. Shen SY, Josselson J, McRoy C, et al. Effects of thymosin alpha 1 on peripheral T-cell and Heptavax-B vaccination in previously non-responsive hemodialysis patients. Hepatology 1987;7:1120.